# Senate Leaders Urge Drug-Price Bills

Senate Judiciary Committee leaders Chuck Grassley and Dick Durbin urged Congress to pass six bipartisan bills addressing patent-system practices and citizen petitions that can affect generic-drug approvals. The bills cleared the committee the previous year, but the article says time to advance them was running short; it identifies no procurement action, solicitation, contract value, or award. If enacted, the measures could affect the generic-drug market and have downstream relevance to public-sector pharmaceutical purchasing, but no direct purchasing change is specified.

- Federal procurement teams and contractors should distinguish this legislative push from an active procurement opportunity: the signal names no acquisition, funding, or solicitation.
- Pharmaceutical suppliers and government buyers may find the proposals relevant to future generic-drug availability and purchasing markets, but the signal does not quantify potential price or supply effects.

**Jurisdictions:** federal
**Industries:** Healthcare
**Topics:** Policy
**Published:** November 17, 2026

### Government Entities
- U.S. Senate Judiciary Committee
